A063160 Stock Overview
Engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CKD Bio Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩22,300.00 |
| 52 Week High | ₩35,700.00 |
| 52 Week Low | ₩19,710.00 |
| Beta | 1.15 |
| 1 Month Change | -1.98% |
| 3 Month Change | -25.17% |
| 1 Year Change | -2.83% |
| 3 Year Change | -46.14% |
| 5 Year Change | -24.41% |
| Change since IPO | 512.16% |
Recent News & Updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Shareholder Returns
| A063160 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.8% | -0.5% | -1.9% |
| 1Y | -2.8% | 0.8% | -9.5% |
Return vs Industry: A063160 underperformed the KR Pharmaceuticals industry which returned 2.4% over the past year.
Return vs Market: A063160 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A063160 volatility | |
|---|---|
| A063160 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A063160 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A063160's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 519 | Hui Kang | www.ckdbio.com |
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products.
CKD Bio Corp. Fundamentals Summary
| A063160 fundamental statistics | |
|---|---|
| Market cap | ₩122.34b |
| Earnings (TTM) | -₩23.13b |
| Revenue (TTM) | ₩159.93b |
0.8x
P/S Ratio-5.3x
P/E RatioIs A063160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A063160 income statement (TTM) | |
|---|---|
| Revenue | ₩159.93b |
| Cost of Revenue | ₩152.99b |
| Gross Profit | ₩6.95b |
| Other Expenses | ₩30.08b |
| Earnings | -₩23.13b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.22k |
| Gross Margin | 4.35% |
| Net Profit Margin | -14.46% |
| Debt/Equity Ratio | 119.5% |
How did A063160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:52 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CKD Bio Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung-rae Han | Daishin Securities Co. Ltd. |
| Sang-Hun Lee | iM Securities |
| Han Kyung Kim | LS Securities Co., Ltd. |